SCHEMBL18220176

SCHEMBL18220176

COCCNS(=O)(=O)/C(C#N)=C(\C)c1ccc(-c2ccc3cc(N4CCN(C)CC4)ccc3c2)s1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.43
ERN1 O75460 1/20 0.35
PRKD1 Q15139 2/20 0.34
RXFP1 Q9HBX9 2/20 0.33
HTR3A P46098 1/20 0.33
GUSB P08236 1/20 0.33
FLT3 P36888 1/20 0.33
POLB P06746 1/20 0.31
ATM Q13315 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
GAA P10253 1/20 0.31
ABL1 P00519 1/20 0.31
CTSK P43235 3/20 0.31
CTSL P07711 2/20 0.31
CTSB P07858 2/20 0.31
CTSS P25774 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18220166 0.93 APP (0.42) APPRXFP1GUSBALDH1A1MAPT
SCHEMBL18220182 0.91 APP (0.43) APPERN1ALDH1A1MAPTMEN1
SCHEMBL18220291 0.85 ERN1 (0.34) APPERN1PRKD1HTR3AFLT3
SCHEMBL24068456 0.85 APP (0.38) APPERN1GUSBALDH1A1MAPT
SCHEMBL18221454 0.85 ERN1 (0.34) APPERN1PRKD1HTR3AFLT3
SCHEMBL18220008 0.84 APP (0.48) APPPRKD1RXFP1HTR3APOLB
SCHEMBL18220153 0.84 APP (0.47) APPERN1PRKD1RXFP1HTR3A
SCHEMBL18220148 0.83 APP (0.43) APPERN1PRKD1POLBALDH1A1
SCHEMBL18220189 0.83 APP (0.43) APPERN1PRKD1RXFP1ATM
SCHEMBL18220195 0.83 APP (0.43) APPPRKD1RXFP1HTR3AGUSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885ERN1 1777/4885PRKD1 3969/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885ERN1 1777/4885PRKD1 3969/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA APP 1/4885ERN1 1745/4885PRKD1 4009/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA APP 1/4885ERN1 1745/4885PRKD1 4009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.